Science News
from research organizations

Future medicinal chemistry shines the spotlight on schistosomiasis

Date:
July 27, 2015
Source:
Future Science Group
Summary:
Leading experts explore current and potential new treatment options for the deadly neglected tropical disease schistosomiasis. Schistosomiasis is the world's most deadly neglected tropical disease, killing an estimated 280,000 people annually in the African region alone, and is the second most common parasitic disease after malaria.
Share:
FULL STORY

In a special free issue of Future Medicinal Chemistry, leading experts explore current and potential new treatment options for the deadly neglected tropical disease schistosomiasis. The journal is published by Future Science Group.

In this issue, experts discuss drug discovery and development advances towards addressing schistosomiasis, also known as bilharzia, a disease caused by parasitic worms. Schistosomiasis is the world's most deadly neglected tropical disease, killing an estimated 280,000 people annually in the African region alone, and is the second most common parasitic disease after malaria. Clinicians now rely solely on the drug praziquantel for treatment and control of schistosomiasis.

"This special focus issue of Future Medicinal Chemistry is impressive for the breadth of contributor expertise in the field of schistosomiasis," said guest editor Conor Caffrey, of the University of California, San Francisco, USA. "Insight is provided by leaders directly involved in disease surveillance and drug implementation programs and by key research innovators and facilitators working in academia, industry and non-governmental organizations."

The issue delivers a wide range of content, including opinion pieces on emerging aspects of the field, such as the rise of open source drug discovery models in neglected disease treatment, and high quality reviews on new antischistosomal drug candidates, as well as discussion on the existing treatment, praziquantel. While known as the "wonder drug" for treating this disease, praziquantel is not without its drawbacks, which the medicinal chemistry community is working to address. In addition, the widespread use of the drug has led to fears that clinical resistance might soon emerge, serving to emphasize the need for alternative treatments.

"The topics covered here communicate not just the excellence and breadth of the research being undertaken but also the spirit of cooperation, dynamism and 'can-do' attitude in a field that has languished somewhat in attention relative to other diseases of poverty," commented Caffrey.

"In view of the lack of funds in this field, we decided to make this special issue free to access in the hope that it will encourage further research towards the treatment and control of schistosomiasis," said Hannah Coaker, managing commissioning editor of Future Medicinal Chemistry.


Story Source:

Materials provided by Future Science Group. Note: Content may be edited for style and length.


Journal Reference:

  1. Conor R Caffrey. Schistosomiasis and its treatment. Future Medicinal Chemistry, 2015; 7 (6): 675 DOI: 10.4155/fmc.15.27

Cite This Page:

Future Science Group. "Future medicinal chemistry shines the spotlight on schistosomiasis." ScienceDaily. ScienceDaily, 27 July 2015. <www.sciencedaily.com/releases/2015/07/150727120320.htm>.
Future Science Group. (2015, July 27). Future medicinal chemistry shines the spotlight on schistosomiasis. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/07/150727120320.htm
Future Science Group. "Future medicinal chemistry shines the spotlight on schistosomiasis." ScienceDaily. www.sciencedaily.com/releases/2015/07/150727120320.htm (accessed May 23, 2017).

RELATED STORIES